GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Helix BioPharma HBP.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

0.90

0.00%

Close of 6 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Helix BioPharma

Its shares trade on Toronto Stock Exchange under the ticker HBP.TO. It has been listed since 3 June 1996.

Helix BioPharma Corp. is an immuno-oncology company, which develops products for the treatment and prevention of cancer. The company is headquartered in Richmond Hill, Ontario. The firm is developing products for the prevention and treatment of cancer based on its technologies. The firm's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The firm's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
3 Jun 1996
Employees
10

Leadership

Pay as last reported

  • Mr. Jacek AntasChairman of the Board, since 2022
  • Mr. Thomas MehrlingChief Executive Officer, Director, since 2025
  • Mr. Rohit BabbarChief Financial Officer
  • Ms. Veronika KandzioraChief Operating Officer
  • Mr. Janusz GrabskiIndependent Director
  • Ms. Malgorzata LaubeIndependent Director
  • Mr. Jerzy LeszczynskiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing L-DOS47 for NSCLC with clinical studies in Poland and US
  • DOS47 technology platform yielding two drug candidates L-DOS47 and vDOS47
  • 10 full-time employees focused on immuno-oncology research and development

Weaknesses

  • Limited employee count of 10 full-time staff
  • Only two drug candidates currently in development
  • Dependence on regulatory approvals in Poland and US for clinical studies

Opportunities

  • Expansion of L-DOS47 clinical studies in Poland and US markets
  • Growth potential in immuno-oncology sector for cancer treatments
  • Development of additional drug candidates from DOS47 platform

Threats

  • Regulatory delays in Poland and US approval processes
  • Competition from other biotechnology firms in cancer treatment
  • Limited resources for scaling up production and clinical trials

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.